Xenon Pharmaceuticals Inc.
XENE
$42.88
-$0.63-1.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 42.04% | 42.00% | 31.99% | 25.60% | 19.06% |
| Gross Profit | -38.13% | -37.78% | -27.63% | -25.60% | -19.06% |
| SG&A Expenses | 18.97% | 22.44% | 41.22% | 48.05% | 49.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.30% | 37.09% | 34.12% | 30.48% | 25.44% |
| Operating Income | -33.37% | -33.93% | -30.78% | -30.48% | -25.44% |
| Income Before Tax | -44.83% | -41.76% | -35.36% | -30.51% | -22.90% |
| Income Tax Expenses | -655.61% | -1,443.11% | -2,296.47% | -1,300.34% | -142.40% |
| Earnings from Continuing Operations | -43.56% | -39.77% | -33.32% | -28.48% | -21.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.56% | -39.77% | -33.32% | -28.48% | -21.90% |
| EBIT | -33.37% | -33.93% | -30.78% | -30.48% | -25.44% |
| EBITDA | -33.80% | -35.01% | -31.84% | -31.47% | -26.08% |
| EPS Basic | -38.30% | -29.45% | -18.59% | -10.19% | -5.63% |
| Normalized Basic EPS | -39.42% | -30.82% | -19.25% | -9.77% | -3.35% |
| EPS Diluted | -38.30% | -29.45% | -18.59% | -10.19% | -5.63% |
| Normalized Diluted EPS | -39.42% | -30.82% | -19.25% | -9.77% | -3.35% |
| Average Basic Shares Outstanding | 4.00% | 7.80% | 11.90% | 16.45% | 15.16% |
| Average Diluted Shares Outstanding | 4.00% | 7.80% | 11.90% | 16.45% | 15.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |